Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Moodys
Boehringer Ingelheim
Dow
AstraZeneca

Last Updated: March 30, 2023

Details for Patent: 8,067,451


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions


Which drugs does patent 8,067,451 protect, and when does it expire?

Patent 8,067,451 protects DUEXIS and is included in one NDA.

This patent has twenty-five patent family members in fifteen countries.

Summary for Patent: 8,067,451
Title:Methods and medicaments for administration of ibuprofen
Abstract: A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
Inventor(s): Tidmarsh; George (Portola Valley, CA), Golombik; Barry L. (Incline Village, NV), Sharma; Puneet (Gaithersburg, MD)
Assignee: Horizon Pharma USA, Inc. (Northbrook, IL)
Application Number:11/779,204
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,067,451
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Process; Use;

Drugs Protected by US Patent 8,067,451

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,067,451

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 539747 ⤷  Sign Up
Australia 2006269894 ⤷  Sign Up
Australia 2007275360 ⤷  Sign Up
Brazil PI0714937 ⤷  Sign Up
Canada 2615496 ⤷  Sign Up
Canada 2657928 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
McKesson
Baxter
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.